Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

SEABIRD EXPLORAT Stock Bullish By 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of SEABIRD EXPLORAT (Oslo Børs All-share Index_GI: SBX.OL) jumped by a staggering 27.96% in 21 sessions from 3.38 kr to 4.32 kr at 19:40 EST on Friday, following the last session's upward trend. Oslo Børs All-share Index_GI is rising 0.37% to 1,418.24 kr, after three consecutive sessions in a row of losses.

About SEABIRD EXPLORAT

SeaBird Exploration Plc, together with its subsidiaries, provides marine 2D and 3D seismic data for the oil and gas industry in Europe, Africa, the Middle East, North and South America, and the Asia Pacific. The company offers 2D seismic, and 3D and 3D shallow water acquisition services; and source vessels that provide conventional undershoot, 4D repeat survey, wide azimuth, push reverse, long-term charter and vessel management, in-house source modelling and environmental decay analysis, and spot charter services. It also engages in the marine minerals business. The company was founded in 1996 and is based in Nicosia, Cyprus.

More news about SEABIRD EXPLORAT (SBX.OL).

Categories

stockMarket

Tags

SEABIRD EXPLORATStock PriceMarket Session NowSBX.OLStock Market NowPrice UpMarket SessionStock Price UpStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com